Search Login Register

Dactinomycin (Ac-De) Summary

Description: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)

Also Known As: Ac-De; Actinomycin; Actinomycin D; Cosmegen; Cosmegen Lyovac Show All >>

Networked: 1691 relevant articles (64 outcomes, 169 trials/studies) for this Drug

Key Diseases for which Dactinomycin is Relevant

  1. Neoplasms (Cancer) : 16 outcomes 29 studies in 380 results
  2. Wilms Tumor (Wilm's Tumor) : 6 outcomes 22 studies in 93 results
  3. Melanoma (Melanoma, Malignant) : 4 outcomes 9 studies in 64 results
  4. Lymphoma (Lymphomas) : 4 outcomes 2 studies in 19 results
  5. Ewing's Sarcoma (Sarcoma, Ewing) : 3 outcomes 7 studies in 23 results
Show All >>

Drugs Related to Dactinomycin

  1. Vincristine (Oncovin)
  2. Cyclophosphamide (Cytoxan)
  3. Doxorubicin (Adriamycin)
  4. Etoposide (VP 16)
  5. Methotrexate (Mexate)
  6. Cisplatin (Platino)
  7. Ifosfamide
  8. Vinblastine (Vinblastine Sulfate)
  9. Bleomycin (Blenoxane)
  10. Fluorouracil (Carac)
Show All >>

Therapies Related to Dactinomycin

  1. Drug Therapy (Chemotherapy)
  2. Combination Drug Therapy (Combination Chemotherapy)
  3. Radiotherapy
  4. Aftercare (After-Treatment)
  5. Adjuvant Chemotherapy
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.